Clinical trials: Drug Administration, Inhalation
Pulmonary Disease, Chronic Obstructive
The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
The primary objective of the trial is to show superiority in lung function of once daily (2 inhalations) treatment with orally inhaled tiotropium+olodaterol fixed dose combination to twice daily (one inhalation) treatment with…
- Trial name
- NCT03240575
- Testing
- Tiotropium, Olodaterol, Fluticasone propionate
- Where
- 45 sites in United States
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone
A study to evaluate the effect of SB-656933-AAA on the body after a single dose in subjects who have been challenged with ozone.
- Trial name
- NCT00551811
- Testing
- SB-656933-AAA
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bioequivalence
A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT04466176
- Testing
- Test Product, Reference Product
- Where
- Greece
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
COPD
Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD
The aim of the current study is to compare the efficacy and safety of Salmeterol/Fluticasone 50/500 mcg Inhalation Powder treatment administered via Capsair twice daily and original product Seretide Diskus 500 mcg Inhalation…
- Trial name
- COPD (NCT03363503)
- Testing
- Salmeterol/Fluticasone Capsair®, Salmeterol/Fluticasone Diskus®
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Bioequivalence
A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT03820180
- Testing
- Test Product, Reference Product
- Where
- Greece
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Asthma, Chronic Obstructive Pulmonary Disease
Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.
Interventional, Prospective, National, Multicentre, Randomised, Open-label, Controlled Clinical Study Comparing Two Parallel Groups, One Control Arm (Standard Treatment) Versus Intervention Arm (Standard Treatment + Study…
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Long COVID
- Trial name
- NCT05601180
- Testing
- Respicure®, Standard of care
- Where
- 8 sites in Algeria
- Volunteers
- 402 people
- Sponsor
- Beker Laboratories
Bioequivalence
A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade
Bioequivalence study between two inhaler products (discus) of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT04124094
- Testing
- Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals), Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK), Activated Charcoal suspension
- Where
- Greece
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Healthy
Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension)
This study aims to demonstrate the bioequivalence between the formulation of Budesonide 1mg/2mL nebuliser suspension (IMP 08P1707F0) relaive to the reference product Pulmicort(r) 1.0mg/2mL suspension.
- Trial name
- BUNIPILOT (NCT06595121)
- Testing
- budesonide, Activated Charcoal
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Unither Pharmaceuticals, France
Asthma
Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects…
- Trial name
- NCT01165138
- Testing
- Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder
- Where
- 70 sites in United States, Germany and 4 more
- Volunteers
- 612 people
- Sponsor
- GlaxoSmithKline
Idiopathic Parkinson's Disease
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an…
- Trial name
- NCT01777555
- Testing
- CVT-301
- Where
- 22 sites in United States, Italy and 2 more
- Volunteers
- 89 people
- Sponsor
- Acorda Therapeutics
Asthma
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma
A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents not…
- Trial name
- NCT01436071
- Testing
- Fluticasone furoate 50mcg
- Where
- 24 sites in United States, Mexico and 2 more
- Volunteers
- 248 people
- Sponsor
- GlaxoSmithKline
Asthma
BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient
The purpose of the study is to demonstrate the Pharmacodynamic bioequivalence of the test product to the reference product in adult patient with Asthma
- Trial name
- NCT05322707
- Testing
- Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg, Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol
- Where
- United States
- Volunteers
- 1,485 people
- Sponsor
- Cipla Ltd.
Bioequivalence
A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT03894280
- Testing
- Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals, SERETIDE DISKUS® 250/50 inhalation powder/GSK, Activated Charcoal suspension
- Where
- Greece
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Bronchial Asthma
To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma
This is a randomized, assessor-blind, placebo controlled, multicenter, clinical endpoint bioequivalence study to compare the efficacy and safety of generic fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark…
- Trial name
- NCT05363202
- Testing
- Fluticasone propionate Inhalation Aerosol 44 mcg, FLOVENT HFA 44 mcg
- Where
- 11 sites in India
- Volunteers
- 790 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Asthma, Bioequivalence
A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions
Bioequivalence study between two inhaler products of ffluticasone propionate inhalation powder
- Trial name
- NCT05397834
- Testing
- Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, FLOVENT DISKUS
- Where
- Greece
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Bioequivalence
A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT04462822
- Testing
- Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 250/50
- Where
- Greece
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Bioequivalence
A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
ioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT04546256
- Testing
- Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 500/50
- Where
- Greece
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Pulmonary Disease, Chronic Obstructive
Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients
This study is designed to determine the efficacy and safety of a new long-acting beta-agonist for asthma patients (GSK159797) following dosing for 14 days.
- Trial name
- NCT00358488
- Testing
- GSK159797 (10, 15, and 20mcg), salbutamol, salmeterol 50mcg
- Where
- 6 sites in Germany, Netherlands and 3 more
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients
In order to obtain information on a wider range of doses of GW642444 (a possible new medication to treat asthma) than has been previously examined in asthmatic patients, this current study will be conducted at doses of 25 100 and…
- Trial name
- NCT00347139
- Testing
- GW642444 (25, 100 & 400 mcg/day), Salmeterol 50mcg
- Where
- 7 sites in Germany, New Zealand and 3 more
- Volunteers
- 55 people
- Sponsor
- GlaxoSmithKline
Pharmacokinetics, Epinephrine
Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals
To assess the drug exposure profile in systemic circulation of Primatene Mist by inhalation, versus Epinephrine by intramuscular injection, and ProAir HFA by inhalation in healthy adults.
- Conditions
- Pharmacokinetics, Epinephrine, Albuterol, Asthma
- Trial name
- NCT04207840
- Testing
- Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.